Visualitzant l d'Hebron Barcelona Hospital Campus

Obeid-Coronal Malalignment Classification Is Age Related and Independently Associated to Personal Reported Outcome Measurement Scores in the Nonfused Spine

Kieser, David Christopher; Hayashi, Kazunori; Cawley, Derek; Yilgor, Caglar; Pellisé Uriquiza, Ferran; Bourghli, Anouar; Boissiere, Louis (Korean Spinal Neurosurgery Society, 2021-09)

Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status

García-Estévez, Laura; Cortés Castan, Javier; Pérez, Silvia; Calvo, Isabel; Gallegos, Isabel; Moreno-Bueno, Gema (Frontiers Media, 2021-08-13)

Obesity Weight Loss Phenotypes in CKD: Measured GFR and Albumin-to-Creatinine Excretion Ratio Place for Stratification

Fontalvo Montoya, Edwin; Machado, Miriam; Lopez Martinez, Marina; Soler, María José (Elsevier, 2023-11)

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

Bosch Albareda, Francesc; Cantin, Guy; Cortelezzi, Agostino; Knauf, Wolfgang; Tiab, Mourad; Turgut, Mehmet (Springer Nature, 2020-02)

Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)

Blanch, Salvador; Gil Gil, Miguel J.; Arumí De Dios, Míriam; SEGUI PALMER, MIQUEL ANGEL; Atienza, Manuel; AGUIRRE, ELENA (Springer, 2023-10)

Observational study on fluid therapy management in surgical adult patients

Colomina, Maria Jose; Ripollés‑Melchor, Javier; Guilabert Sanz, Patricia; Jover Pinillos, Jose Luis; Basora, M.; Cassinello, Concepción (BMC, 2021-12-13)

Occupational radiation exposure of electrophysiology staff with reproductive potential and during pregnancy: an EHRA survey

Adeliño, Raquel; Malaczynska-Rajpold, Katarzyna; Perrotta, Laura; Manninger, Martin; Vanduynhoven, Philippe; Nesti, Martina (Oxford University Press, 2023-08-02)

Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension

Kappos, Ludwig; Li, David K B; Bar-Or, Amit; Barkhof, Frederik; Traboulsee, Anthony; Montalban, Xavier (Springer, 2024-02)

Off-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study

Sans Pola, Carla; Agustí Escasany, Maria Antònia; Bosch Gil, José Ángel; Agraz Pamplona, Irene; Alerany Pardo, Carme; Danes Carreras, Immaculada (MDPI, 2021-10-26)

Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review

Sans-Pola, Carla; Danés Carreras, Immaculada; Bosch, Josep Àngel; Marrero Álvarez, Patricia; Cortes Hernandez, Josefina; Agustí, Antònia (Frontiers Media, 2023-05-25)

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Ring, Alistair; Kilburn, Lucy; Pearson, Alex; Moretti, Laura; Afshari-Mehr, Angelica; Wardley, Andrew; Llop Guevara, Alba; Serra, Violeta (American Association for Cancer Research, 2023-12-01)

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

Fizazi, Karim; Saad, Fred; Mateo, Joaquin; de Bono, Johann S; Shore, Neal; Sandhu, Shahneen (American Society of Clinical Oncology, 2024-02-10)

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)

Perez-Fidalgo, J. A.; Cortés, A.; Guerra, Eva; García, Y.; Iglesias, M.; Bohn Sarmiento, U.; Oaknin Benzaquen, Ana Mazaltob (Elsevier, 2021-08)

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Mateo Valderrama, Joaquim; Porta, Nuria; Bianchini, Diletta; McGovern, Ursula; Elliott, Tony; Jones, Robert (Elsevier, 2020-01-01)

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

Poveda, Andres; Lheureux, S.; Cibula, David; Weberpals, J.; Oaknin Benzaquen, Ana Mazaltob; Colombo, Nicoletta; Lindemann, Kristina (Elsevier, 2022-03)

Old zoonotic agents and novel variants of tick-borne microorganisms from Benguela (Angola), July 2017

Palomar, Ana M.; Bocanegra García, Maria Cristina; Portillo, Aránzazu; Salvador Velez, Fernando M; Moreno, María Milagros; Oteo, José A.; Molina Romero, Israel (BMC, 2022-04-21)

Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome

Makhani, Naila; Lebrun, Christine; Siva, Aksel; Narula, Sona; Wassmer, Evangeline; Brassat, David; Tintore Subirana, Mar (SAGE Publications, 2019-03-20)

Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study

Park, Keunchil; Jӓnne, Pasi A.; Kim, Dong-Wan; Han, Ji-Youn; Wu, Ming-Fang; Lee, Jong-Seok; Felip Font, Enriqueta (Wiley, 2021-05-01)

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

de la Fuente, Macarena; Colman, Howard; Rosenthal, Mark; Van Tine, Brian; Levacic, Danijela; Walbert, Tobias; Vieito Villar, Maria (Oxford University Press, 2023-01)

On the clinical relevance of using complete high-resolution HLA typing for an accurate interpretation of posttransplant immune-mediated graft outcomes

Meneghini, Maria Antonia Emilia; Perona, Anna; Crespo Gimeno, Elena Isabel; Bemelman, Frederike; Reinke, Petra; Viklicky, Ondrej; Torija Recasens, Alba; Donadeu Casassas, Laura; Zuñiga-Vergara, Jose-Miguel; Bestard Matamoros, Oriol (Frontiers Media, 2022-09-29)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Visualitzant Vall d'Hebron Barcelona Hospital Campus - VH per títol

Obeid-Coronal Malalignment Classification Is Age Related and Independently Associated to Personal Reported Outcome Measurement Scores in the Nonfused Spine

Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status

Obesity Weight Loss Phenotypes in CKD: Measured GFR and Albumin-to-Creatinine Excretion Ratio Place for Stratification

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)

Observational study on fluid therapy management in surgical adult patients

Occupational radiation exposure of electrophysiology staff with reproductive potential and during pregnancy: an EHRA survey

Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension

Off-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study

Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

Old zoonotic agents and novel variants of tick-borne microorganisms from Benguela (Angola), July 2017

Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome

Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

On the clinical relevance of using complete high-resolution HLA typing for an accurate interpretation of posttransplant immune-mediated graft outcomes

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Visualitzant Vall d'Hebron Barcelona Hospital Campus - VH per títol

Obeid-Coronal Malalignment Classification Is Age Related and Independently Associated to Personal Reported Outcome Measurement Scores in the Nonfused Spine ﻿

Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status ﻿

Obesity Weight Loss Phenotypes in CKD: Measured GFR and Albumin-to-Creatinine Excretion Ratio Place for Stratification ﻿

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study ﻿

Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS) ﻿

Observational study on fluid therapy management in surgical adult patients ﻿

Occupational radiation exposure of electrophysiology staff with reproductive potential and during pregnancy: an EHRA survey ﻿

Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension ﻿

Off-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study ﻿

Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review ﻿

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010) ﻿

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial ﻿

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study) ﻿

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial ﻿

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis ﻿

Old zoonotic agents and novel variants of tick-borne microorganisms from Benguela (Angola), July 2017 ﻿

Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome ﻿

Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study ﻿

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial ﻿

On the clinical relevance of using complete high-resolution HLA typing for an accurate interpretation of posttransplant immune-mediated graft outcomes ﻿

Coneix Scientia

Guies i ajudes

Directe a...

Coneix Scientia

Guies i ajudes

Directe a...

Obeid-Coronal Malalignment Classification Is Age Related and Independently Associated to Personal Reported Outcome Measurement Scores in the Nonfused Spine

Obesity and Breast Cancer: A Paradoxical and Controversial Relationship Influenced by Menopausal Status

Obesity Weight Loss Phenotypes in CKD: Measured GFR and Albumin-to-Creatinine Excretion Ratio Place for Stratification

Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study

Observational study of HR+/HER2− metastatic breast cancer patients treated with abemaciclib in Spain in the Named Patient Use Program (AbemusS)

Observational study on fluid therapy management in surgical adult patients

Occupational radiation exposure of electrophysiology staff with reproductive potential and during pregnancy: an EHRA survey

Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension

Off-Label Use of Rituximab in Patients with Different Types of Nephropathies in a Tertiary Hospital: A Retrospective Study

Off-label use of rituximab in patients with systemic lupus erythematosus with extrarenal disease activity: a retrospective study and literature review

Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis

Old zoonotic agents and novel variants of tick-borne microorganisms from Benguela (Angola), July 2017

Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome

Olmutinib in T790M-positive non–small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

On the clinical relevance of using complete high-resolution HLA typing for an accurate interpretation of posttransplant immune-mediated graft outcomes